![HC-2013-000089 - [2025] EWHC 2376 (Ch)](https://backend.juristeca.com/files/emisores/logo_O3rEzCI.png){kind=logo}
Heading
Neutral Citation Number: [2025] EWHC 2376 (Ch)
Case No: HC-2013-000089
IN THE HIGH COURT OF JUSTICE
BUSINESS AND PROPERTY COURTS OF ENGLAND AND WALES
INTELLECTUAL PROPERTY LIST (ChD)
Rolls Building
Fetter Lane
London, EC4A 1NL
19 September 2025
Before :
MRS JUSTICE BACON
Between :
MERCK KGaA
Claimant
- and -
(1) MERCK SHARP & DOHME LLC
(2) MERCK & CO., INC.
(3) ORGANON PHARMA (UK) LIMITED
(formerly “MERCK SHARP & DOHME LIMITED”)
(4) MSD ANIMAL HEALTH UK LIMITED
(formerly “INTERVET UK LIMITED”)
(5) INTERVET INTERNATIONAL B.V.
Defendants
Benet Brandreth KC and David Ivison (instructed by Bird & Bird LLP) for the Claimant
Geoffrey Hobbs KC and Guy Hollingworth (instructed by Linklaters LLP) for the Defendants
Hearing dates: 8–11 and 16 July 2025
Approved Judgment
- Heading
- Section 1
- Witnesses
- MSD’s witnesses of fact
- Expert evidence
- Factual and procedural history
- The Merck companies
- The 1955 and 1970 Agreements
- The present proceedings and previous judgments
- Relevant findings of breach and infringement
- Issues
- Relevant law
- The relevant counterfactual
- General approach to uncertainties in the evidence
- Appropriateness of licence fee damages in the present case
- The assessment of licence fee damages: overview
- Comparables approach
- The criticisms of Mr Wynn’s analysis
- Mr Wynn’s cross-examination
- Merck’s closing submissions
- Economic benefits approach
- General approach
- Avoided costs of email address migration
- Avoided website costs
- Avoided social media costs
- Web traffic gain
- Avoided marketing costs
- Avoided staff training costs
- Unquantifiable benefits
- Inflation adjustment
- Discount rate
- Conclusions